Huawei and Guangzhou Pharmaceutical Holdings are collaborating to use AI and Ascend chips for drug discovery validation.
4 reports, 1 independent
Updated Aug 27
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Huawei and Guangzhou Pharmaceutical Holdings are collaborating to use AI and Ascend chips for drug discovery validation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Huawei
Chinese multinational technology company
-
ASCEND
open source, mathematical modelling chemical process modelling system
Nothing else this week.
-
Guangzhou Pharmaceutical Holdings
pharmaceutical wholesaling and distribution company
Nothing else this week.
Related events
- Trump's administration imposed export restrictions on China while Chinese AI firms like Alibaba and DeepSeek continue to develop competing models.
- US tech companies, including AMD, are leading China in AI chip development, leading to agreements on export licenses and profit sharing.
- Huawei is being evaluated alongside competitors like Nvidia for a potential role in Malaysia's national AI program within the competitive Southeast Asian market.
- Huawei supported the inaugural conference on AI adoption in Malaysia.
- Huawei presented future network plans in Shanghai, noting that the network architecture supports AI application growth.